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REVIEW
Ketamine: synaptogenesis, immunomodulation and glycogen
synthase kinase-3 as underlying mechanisms of its
antidepressant properties
PA Zunszain, MA Horowitz, A Cattaneo, MM Lupi and CM Pariante
Major depressive disorder is an extremely debilitating condition affecting millions of people worldwide. Nevertheless, currently
available antidepressant medications still have important limitations, such as a low response rate and a time lag for treatment
response that represent a signiﬁcant problem when dealing with individuals who are vulnerable and prone to self-harm. Recent
clinical trials have shown that the N-methyl-D-aspartate receptor antagonist, ketamine, can induce an antidepressant response
within hours, which lasts up to 2 weeks, and is effective even in treatment-resistant patients. Nonetheless, its use is limited due to
its psychotomimetic and addictive properties. Understanding the molecular pathways through which ketamine exerts its
antidepressant effects would help in the developing of novel antidepressant agents that do not evoke the same negative side
effects of this drug. This review focuses speciﬁcally on the effects of ketamine on three molecular mechanisms that are relevant to
depression: synaptogenesis, immunomodulation and regulation of glycogen synthase kinase-3 activity.
Molecular Psychiatry (2013) 18, 1236–1241; doi:10.1038/mp.2013.87; published online 23 July 2013
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INTRODUCTION
Recent clinical research has provided evidence demonstrating that
low-dose intravenous infusions of ketamine, a drug originally
developed as an anaesthetic,1 can improve depressive symptoms
within hours in subjects with treatment-resistant depression.2
Interestingly, the effects have been shown to last from a couple of
days up to several weeks.3–5 This is a crucial step forward in the
treatment of depression, among the greatest challenges that
modern medicine has ever been forced to face, thought to affect
up to 350 million people worldwide.6 The antidepressant
medications available today exhibit low rates of treatment
response, with only one in three people responding to their ﬁrst
prescribed medication and two in three people responding after
trying numerous alternatives.7 More importantly, therapeutic
effects display a response lag time of several weeks, a
signiﬁcant problem in those individuals who are particularly
vulnerable to self-harm and suicide. For these reasons, there is a
pressing need to identify novel antidepressant drugs that are fast
acting and show better rates of response.
Despite the promising rapid antidepressant action, ketamine
has psychotomimetic and addictive properties that limit its
potential widespread use as a fast-acting antidepressant drug.
Indeed, ketamine has been shown to induce psychosis in healthy
subjects8 and to exacerbate psychotic symptoms in individuals
affected by schizophrenia,9 and has also been abused as a ‘club
drug’.10 Elucidating the molecular pathways via which ketamine
mediates its antidepressant effects would facilitate the
development of other pharmacological agents with similar
beneﬁciary properties but without the unwanted side effects.
A recent review11 has discussed the putative synaptic actions of
the drug. Here we focus on three speciﬁc molecular mechanisms
that are potentially involved in the antidepressant action of
ketamine: increased neuroplasticity and synaptogenesis via
enhancement of glutamatergic signaling, changes in immune
function and (more preliminary) regulation of glycogen synthase
kinase-3 (GSK-3) activity.
KETAMINE ACTS VIA SYNAPTOGENESIS PROMOTION
THROUGH ENHANCED GLUTAMATERGIC SIGNALING
Ketamine is classiﬁed pharmacologically as an N-methyl-D-
aspartate (NMDA) receptor antagonist. The ﬁrst indication that
the NMDA receptor may be a useful target for antidepressant
treatment came from observations that the anti-tuberculosis drug,
cycloserine, a partial agonist of the glycine site of the NMDA
receptor, improved mood in those tuberculosis-affected patients
who were also depressed.12 It subsequently took more than 30
years to develop the hypothesis that compounds altering NMDA
function could have antidepressant properties13 and therefore
that glutamate, its main ligand, may be involved in the
pathophysiology of depression. The NMDA receptor is a speciﬁc
type of ionotropic glutamate receptor. However, it has been
suggested that other glutamatergic receptors may be involved in
the action of ketamine. Indeed, when glutamate (L-glutamic acid),
the major excitatory neurotransmitter in the nervous system, is
released from presynaptic neurons, it can interact with different
postsynaptic receptors: kainite, a-amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid (AMPA), and NMDA. Several ﬁndings
support the involvement of both NMDA and AMPA receptors in
the pathophysiology of major depression disorder (MDD) and in
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the mechanisms of action of antidepressants.14–17 Ketamine is
able to increase extracellular glutamate levels in the prefrontal
cortex (PFC) by inhibiting NMDA receptor currents on GABAergic
interneurones, in turn disinhibiting glutamate transmission.18,19
Additionally, ketamine can enhance AMPA receptor throughput.20
In particular, an increase in AMPA/NMDA receptor density ratio
has been observed in the hippocampus of rats after ketamine
treatment.21 Indeed, an enhanced glutamatergic activity trans-
duced through AMPA receptors rather than NMDA receptors may
be responsible for mediating the increased synaptic potentiation
and activation of early neuroplastic genes observed upon
exposure to the drug15 (described below in further detail). Of
note, treatment with NBQX, an AMPA receptor antagonist, has
been shown to inhibit the antidepressant effects of ketamine in
animal models of depression.22,23 Both AMPA and NMDA recep-
tors are important in long-term potentiation and long-term
depression, the two main neurobiological mechanisms which
are responsible for mediating activity-dependent synaptic
plasticity and re-modeling. Long-term potentiation has primarily
been shown to induce dendritic spine growth, and enlargement of
pre-existing spines and of the associated post-synaptic density
proteins,24 all of which are observed upon ketamine exposure.25
Additionally, ketamine inhibits spontaneous NMDA mini-excita-
tory post-synaptic currents caused by spontaneous glutamate
release at rest.26 Interestingly, brain post mortem studies have
described increased glutamate levels in individuals with mood
disorders,27 while decreased hippocampal NMDA receptors have
been described in bipolar patients.28
Ketamine has also been shown to reverse the dendritic atrophy
caused by chronic unpredictable stress exposure, a paradigm
widely used to induce depression-like behavior in rodents. In such
a model, a single dose of ketamine increased the number of
spines on the apical dendrites of PFC layer V pyramidal neurons
and also their function, as demonstrated by increases in serotonin-
and hypocretin-induced excitatory post-synaptic currents. These
changes occurred 2 h after administration of the drug and were
sustained for up to 7 days, a time course comparable to that
reported in clinical trials.5 Concomitantly, the reduced interest in
both sucrose and food that followed chronic unpredictable stress
was completely abolished.29
KETAMINE ACTION ON NEUROTROPHIC FACTORS: BRAIN-
DERIVED NEUROTROPHIC FACTOR (BDNF)
Ketamine has been shown to regulate levels of the neurotrophin
BDNF.30,31 BDNF has a central role in the neurotrophic theory of
depression, which proposes that stress-related reduction in
neurotrophic support, leading to the degeneration of limbic
structures and, in particular, of the PFC and hippocampus,
represents an important factor underlying the pathogenesis of
depression. More speciﬁcally, reductions in BDNF, and of its high
afﬁnity receptor TrkB, have been found both in the blood and the
brains of patients affected by mood disorders; conversely,
antidepressant drugs have shown to act, at least in part, through
a potentiation of BDNF expression and its signaling.32–36 BDNF has
also been associated with the process of neurogenesis, thought to
be impaired in stress and increased by antidepressants.37–39
Additionally, BDNF has been linked to synaptic re-modeling, being
able to both induce and be induced by long-term potentia-
tion.40,41 Animal models have shown that ketamine administration
reduced immobility in the forced swim test, and this behavioral
effect was coupled with increased BDNF protein levels in the
hippocampus.30 Furthermore, circulating BDNF levels were
increased after ketamine administration in treatment-resistant
MDD patients concomitant with mood improvement.42
Interestingly, AMPA receptor agonists have shown similar
actions to ketamine. For example, treatment of primary neuronal
cultures and hippocampal slices with the agonist CX614 led to
increased dendritic protein synthesis, mediated by BDNF secretion
and TrkB receptor activation.43 Additionally, the novel AMPA
receptor potentiator LY392098 has been shown to increase the
expression of BDNF in primary neuronal cultures.44
Several mechanisms have been proposed to explain the
modulation of BDNF induced by ketamine, as schematized in
Figure 1. Ketamine-mediated suppression of resting NMDA
receptor activity can lead to inhibition of eukaryotic elongation
factor 2 (eEF2) kinase and subsequently to a dephosphorylation of
eEF2, with a concomitant augmentation of BDNF synthesis.45
Alternatively, or additionally, the resultant depolarization from
AMPA receptor activity can activate voltage-dependant calcium
channels, allowing calcium inﬂux and exocytosis of BDNF, which
can then activate TrkB receptors, in turn setting off an intracellular
signaling cascade that includes phosphorylation and thus
activation of Akt (also known as protein kinase B) and
extracellular signal-regulated protein kinase (ERK). Both Akt and
ERK are involved in the regulation of synaptic protein synthesis
(described in detail in the next section).44,46 Of note, it has also
been proposed that the upregulation in BDNF and synaptic
protein expression could be due to the de-suppression of
translation and not to activity-dependent BDNF release or
intracellular TrkB signaling.47
SYNAPTIC-RELEVANT SIGNALING PATHWAYS UNDERLYING
KETAMINE-INDUCED SYNAPTOGENESIS: MAMMALIAN TARGET
OF RAPAMYCIN (MTOR)
As the production of synaptic proteins that are important for
neuroplasticity is one of the potentially critical steps for ketamine
action,46 attention has recently turned to those enzymes involved
in their synthesis. One of these enzymes is the serine/threonine
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Figure 1. Schematic representation of mechanisms underlying
ketamine action. Ketamine-mediated suppression of N-methyl-D-
aspartate receptor (NMDA-R) activity leads to inhibition of
eukaryotic elongation factor 2 (eEF2) kinase and a subsequent
dephosphorylation of eEF2, with a concomitant augmentation of
brain-derived neurotrophic factor (BDNF) synthesis. The depolariza-
tion from a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
receptor (AMPA-R) activity activates voltage-dependant calcium
channels (VDCCs), allowing calcium influx and exocytosis of BDNF,
which can then activate TrkB receptors, in turn activating Akt and
extracellular signal-regulated protein kinase (ERK). Akt and ERK
activate mammalian target of rapamycin (mTOR), which enables the
translation of synaptic protein by activating p70S6 kinase and
inhibiting 4E binding proteins (4E-BPs). Glycogen synthase kinase-3
can be released from its inhibition of BDNF expression through
phosphorylation by Akt or p70S6K. See text for additional details.
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kinase mTOR, whose activation is essential in regulating the
expression of several proteins involved in synaptic plasticity.11
Interestingly, reduced synaptic proteins in conjunction with
reduced mTOR signaling have been found in the PFC of
depressed subjects, highlighting the importance of mTOR.48
Therefore, it is worth describing brieﬂy the signaling cascades
that both activate and are activated by it (shown in Figure 1).
mTOR can be phosphorylated by several kinases, including Akt
and ERK, which are both triggered by neurotrophic factor
signaling cascades (as described above). mTOR then enables the
translation of synaptic protein by activating p70S6 kinase and
inhibiting the inhibitory 4E binding proteins (4E-BPs).49,50 Impor-
tantly, administration of ketamine to rats has shown a rapid
induction of phosphorylation of mTOR, p70S6 kinase and 4E-BP1
in synaptoneurosome PFC preparations. This induction was
accompanied by an upregulation of Arc, GluR1, PSD95 and
synapsin I, which are all markers of synaptic plasticity and found to
be decreased upon exposure to stress in the learned helplessness
paradigm of depression.25 The importance of mTOR is emphasized
by results obtained on pre-treatment with the inhibitor rapamycin,
which blocks cell-cycle progression and prevents p70S6 kinase
activation.51,52 This inhibition completely repressed the behavioral
antidepressant effects of ketamine when tested in both the forced
swim test and learned helplessness paradigms.25 In line with this
behavioral effect, rapamycin blocked ketamine induction
of layer V pyramidal PFC neuron spine number and function, as
well as the expression of synaptic proteins. Furthermore,
co-treatment with ketamine and the AMPA receptor antagonist,
NBQX, completely block 4E-PB1, p70S6k, mTOR, ERK and Akt
phosphorylation. The involvement of mTOR or eEF2, however, is
far from clear. A recent study in female rats showed no changes in
the phosphorylation of either of them as mediating the response
to ketamine,53 suggesting that at least some of the underlying
mechanisms may be sex-speciﬁc. It is generally agreed, though,
that ketamine-induced synaptogenesis appears to be a result of
NMDA receptor blockade at rest, which leads to the
de-suppression of translation of rapid dendritic proteins and
BDNF. Of relevance here, BDNF-evoked protein translation in
neuronal dendrites has been reported to be attenuated by both
rapamycin and small interfering RNAs speciﬁc for mTOR.54 It is
important to mention that mTOR can form two complexes—
complex 1 (mTORC1) and complex 2 (mTORC2), deﬁned by the
presence of regulatory-associated protein of mTOR or rapamycin-
independent companion of mTOR, respectively.55,56 Although
publications examining the effects of ketamine on synaptogenesis
have not yet differentiated between these two complexes,
observations with the inhibitor rapamycin would suggest that
studies have indeed focused on mTORC1.51,52 It is theoretically
possible, though, that mTORC2 is also involved in the action of
ketamine as it activates Akt and has downstream effects that are
important in the organization of the actin cytoskeleton.57
However, the above-mentioned ability of a brief pre-treat-
ment with rapamycin to abolish the action of ketamine25
strongly suggests that mTORC1 is the principal effector,
given that rapamycin robustly and rapidly inhibits mTORC1 and
only partially and slowly acts on mTORC2.55 To further understand
both complexes, more speciﬁc blockers would have to be
employed.
KETAMINE IMMUNOMODULATORY ACTIONS
Several reports have shown that ketamine can limit and even
prevent inﬂammation.58 High levels of inﬂammation have been
reported to be important in depression59,60 and appear to
inﬂuence treatment response.61,62 We will describe two main
mechanisms that have been proposed for ketamine: a direct
action on inﬂammatory cytokines and regulators and an involve-
ment in the kynurenine pathway.
A recent meta-analysis has shown that ketamine administration
before or during surgery signiﬁcantly inhibits the early post-
operative interleukin (IL)-6 inﬂammatory response in patients.63
Additionally, ketamine is able to suppress lipopolysaccharide
(LPS)-induced tumor necrosis factor (TNF)-a, IL-6 and IL-8
production in the human whole blood.64 Similar results were
observed upon ketamine treatment of rats, showing an
attenuation of both the increase in TNF-a as well as the increase
in the ratio of IL-6 to IL-10 following an Escherichia coli endotoxin
challenge.65 Further tests in animals have shown suppression of
IL-6 and TNF-a,66 as well as nitric oxide,67 subsequent to an LPS
insult. A series of experiments have shed light into some of the
mechanisms underlying these changes in inﬂammatory markers.
For example, studies in a human monocytic cell line indicated that
the immunoinhibitory effects of ketamine appear to be caused by
inhibition of activation of the transcription factor nuclear factor-
kappa B (NF-kB).68 Interestingly, ketamine has also shown to cause
inhibition of the expression of the Toll-like receptor (TLR) 4, as well
as attenuation of the phosphorylation of p65, one of the subunits
of NF-kB, in astrocytes challenged by LPS.69 In addition, ketamine-
induced inhibition of lipoteichoic acid-induced TNF-a and IL-6 was
also shown to be mediated by inhibition of translocation and
transactivation of NF-kB.70 These effects occurred through
downregulation of TLR2-mediated phosphorylation of ERK1/2.
Additionally, ketamine has displayed inhibition of inﬂammation
via upregulation of the inducible heme oxygenase-1, which can
provide cellular protection by exerting antioxidative effects.71
Ketamine can act through an involvement in the kynurenine
pathway. As mentioned before, ketamine has proven to be
effective in reducing suicidal symptoms,3,72,73 and recent evidence
points toward a low grade of inﬂammation in the brain of suicide
victims.74,75 In particular, signiﬁcantly elevated levels of quinolinic
acid (QUIN), associated with higher levels of IL-6, have been
reported in the cerebrospinal ﬂuid of suicide attempters.76 This
increase in QUIN, an NMDA receptor agonist, correlated with the
scores on the Suicide Intent Scale. QUIN is an end product of
tryptophan metabolism, in which the enzyme indoleamine 2,3-
dioxygenase (IDO), induced by cytokines,77 directs tryptophan
away from serotonin and toward kynurenine. Further metabolism
of kynurenine can then lead to QUIN and also, or alternatively, to
kynurenic acid (KYNA), an NMDA receptor antagonist.
Interestingly, suicidal attempters showed no changes in KYNA
levels. The increased QUIN/KYNA ratio supports the hypothesis of
an overall NMDA receptor stimulation, suggesting that changes in
glutamatergic neurotransmission could be speciﬁcally linked to
suicidality. Further support for the participation of the kynurenine
pathway comes from a recent study in mice. Exposure to ketamine
immediately before or after administration of LPS abrogated the
development of LPS-induced depressive-like behavior (known to
occur via activation of IDO78), without altering the LPS-induced
sickness. Interestingly, ketamine was effective once inﬂammation
and IDO activation had developed. The role of NMDA receptor
antagonism by ketamine was additionally conﬁrmed when mice
pre-treated with the AMPA receptor antagonist NBQX displayed a
restoration of the depressive-like phenotype upon exposure to
both LPS and ketamine.79 A complete evaluation of the regulation
of all enzymes within the kynurenine pathway upon ketamine
administration will be clearly of great interest.
KETAMINE, GSK-3 AND CIRCADIAN RHYTHM ABNORMALITIES
Administration of ketamine to mice has been shown to inhibit
brain GSK-3,80 a kinase that, interestingly, is also a target of mood-
stabilizing agents.81 The inhibition observed upon ketamine
administration occurs via an increase in serine-phosphorylation
of both the a and b isoforms of the enzyme.82 Indeed, animals
with a knock-in mutation that blocks GSK-3 phosphorylation did
not respond to ketamine treatment in the learned helplessness
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paradigm,80 demonstrating that ketamine-induced phosphory-
lation of GSK-3 is required for its antidepressant properties. GSK-3
is, in fact, involved in the same pathway as mTOR, being
phosphorylated and therefore inactivated by both Akt83 and
p70S6K,84 as seen in Figure 1. Furthermore, inhibition of GSK-3 by
either short interference RNA or through pharmacological agents
has also been shown to increase BDNF, thus implicating GSK-3 in
synaptogenesis.85 However, the full role of GSK-3 is still not
clearly understood. For example, the GSK-3 inhibitor SB216763
was not able to produce a long-lasting antidepressant action in
mice subjected to a chronic mild stress paradigm, when compared
with ketamine administration.86 Further research in this area is
warranted.
Other possible mechanisms involving GSK-3 have been
described. Ketamine, through a mechanism that involves this
kinase, is able to inﬂuence the circadian molecular machinery.
Abnormalities in circadian rhythms have been associated with the
pathophysiology of depression. Conversely, therapies like sleep
deprivation, which are capable of phase-shifting behavioral and
physiological rhythms, have been shown to induce rapid
improvement in subsets of depressed patients.87 Ketamine can
modulate the expression of several genes involved in the circadian
rhythm. In particular, it has been shown that acute exposure of
animal neuroblastoma cells to ketamine led to a reduction in the
amplitude of circadian transcription of the genes brain and muscle
aryl hydrocarbon receptor nuclear translocator-like 1 (BMAL1),
period 2 (Per2) and cryptochrom 1.88 Furthermore, ketamine
altered the recruitment of the circadian locomotor output cycles
kaput (CLOCK):BMAL1 complex on circadian promoters. Intere-
stingly, the ketamine-induced repression of CLOCK:BMAL1 was
reduced after treatment with the GSK-3 inhibitor SB216763. Of
note, mTOR, mentioned above as being required for the antide-
pressant effects of ketamine, has been implicated in having a key
role in the entrainment of the suprachiasmatic nucleus (the central
regulator of circadian rhythms in mammals) to light. mTOR is also
involved in the resetting of the circadian clock by regulating the
synthesis of the core circadian gene protein, PER1 and PER2.89
Interestingly, high doses of ketamine have been shown to block
light-induced phase shifts in locomotor activity when
administered to hamsters,90 further suggesting that circadian
rhythm regulation could have an important role underlying the
mode of action of the drug.
CONCLUSION AND FUTURE DIRECTIONS
Here we have described evidence supporting the notion that
ketamine exerts antidepressant properties mainly via modulation
of synaptogenesis and inﬂammation (and possibly GSK-3). In
particular, ketamine is able to improve synaptogenesis by acting
on NMDA and AMPA receptors, and probably through stimulation
of mTOR activity, which in turn triggers the translation of synaptic
proteins required for neuronal plasticity. Additionally, ketamine
potentiates BDNF/TrkB signaling. Moreover, ketamine is
able to reduce inﬂammation, an effect that could occur
via inhibition of NF-kB or by preventing IDO activation and the
possible concomitant shift of tryptophan metabolism toward
neurodegenerative metabolites. Finally, GSK-3 appears to have an
important role, as its inhibition is required for ketamine to convey
its antidepressant effects. Of interest, recent evidence has shown
that the antidepressant effects of ketamine were completely
abolished when female rats were ovariectomized, and restored
upon oestrogen and progesterone supplementation, suggesting a
critical role for gonadal hormones.53 This may be clinically
relevant, as ketamine has already shown sex-speciﬁc differences,
both in rat models of analgesia and catalepsy91 and in human
studies looking at amnestic effects.92 Additional work in this area
is therefore pertinent.
The growing understanding of the mode of action of ketamine
has triggered an increased interest by pharmaceutical companies
in the development of novel and more effective antidepressant
drugs. Indeed, traxoprodil, an NR2B subtype selective NMDA
antagonist,93 and GLYX-13, an NMDA receptor glycine-site
functional partial agonist,94 are some of those. Interestingly,
GLYX-13 is currently in a phase II clinical development programme
for treatment-resistant depression. Given the evidence that
ketamine is effective in cases of suicidal ideation, improved
agents will clearly help to deal with this medical emergency. The
hope that a new type of fast acting antidepressants would bring
to the growing numbers of MDD patients and their worried
families clearly warrants further funding and increased efforts
from the scientiﬁc community and pharmaceutical companies.
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